Triple-negative breast cancer: a potential new treatment is now in sight

3 Views

06/23/23

Breast cancer is the most commonly diagnosed cancer in Australia. Approximately 15,000 women are affected each year, many of whom are under 40. Triple-negative breast cancer (TNBC) is highly invasive, has no current targeted treatment and affects about 15% of those diagnosed with breast cancer.

Garvan is leading a world-first clinical trial of a potential new treatment for TNBC. It could dramatically improve survival rates for patients and even block tumour growth. This clinical trial also has the potential to impact other cancer types such as ovarian, renal, liver and glioblastoma.

This is why your support today is so vital.

https://www.garvan.org.au/support-us/in-our-sights